

ESTD. 1979

CHAIRMAN: David Whittle
VICE CHAIRMAN: Claire George
SECRETARY: Susie Davies
TREASURER: Dawn Reed
WEBMASTER: David Gerrie
CORPORATE LIASON: Jenny Button
ACADEMIC LIASON: Andrew Kicman

FORENSIC REGULATOR

LIASON: Stephen Morley
ORDINARY Simon Walker
MEMBERS: Jane Eastwood
Andrew Clatworthy
Malgorzata Puchnarewicz

FRIDAY 12TH OCTOBER 2012 CHARLES DARWIN HOUSE CONFERENCE CENTRE, LONDON

'DRUGS IN SOCIETY'

Sponsored by



Exhibitors





PROGRAMME

12:30 – 13:30	LUNCH	Academic break out session (to be held in Charles 1 room)
13:30 – 14:00	The use of automated direct sample analysis, DSA-ToF, for the rapid screening of illicit street drugs	Sean Daugherty Perkin Elmer
14:00 – 14:30	Prevalence of drugs in the UK workplace, 2007-2011.	Dr Simon Walker Concateno
14:30 – 15:00	The clinical pharmacology of harm?	Professor Robin Ferner City Hospital University of Birmingham
15:00 – 15:30	TEA	
15:30 – 16:00	Against the Legalisation of Drugs	Dr Anthony Daniels (aka Theodore Dalrymple) Psychiatrist & Writer Formerly City Hospital, Birmingham
16:00 – 16:30 16:30 – 17:00	Misuse of Drugs Act? BUSINESS MEETING	Dr Les King (retired) Formerly Forensic Science Service

Please could all Committee members arrive at 10:30 am for an Executive Committee meeting.

LTG - established for the promotion and advancement for the public benefit of education in the science of analytical toxicology

Dr Les King will cover:

- 1. The Misuse of Drugs Act is not an ideal vehicle for restricting new substances (e.g. inability to carry out a proper risk-assessment in many cases; law not being enforced; the Act being used as a preemptive measure rather than a reaction to specific harm to individuals or society; arguably too many substances now controlled; problems raised by generic control).
- 2. The ABC Classification bears no correlation with the harms of substances (e.g. evidence-based policy replaced by policy-based evidence; overuse of the precautionary principle).
- 3. Problems with Misuse of Drugs Regulations Schedule 1 substances (e.g. the difficulty of doing research and the almost impossible task of ever getting such substances such as psilocybin, MDMA or 2-bromo-LSD accepted into clinical practice; the illogicality of placing methoxetamine (currently a Temporary Class Drug) in Schedule 1.
- 4. The legal problems raised by the concepts of "product" and "preparation".